RESEARCH PEPTIDE FUNDAMENTALS
Frequently asked questions
Common questions about BPC-157, Ipamorelin, Semaglutide and GHK-Cu, answered plainly and with citations.
What does BPC-157 do in the body?
In animal models, BPC-157 promotes the growth of new blood vessels (angiogenesis) via the VEGFR2-Akt-eNOS signaling pathway and supports migration of repair cells into damaged tissue through FAK-paxillin signaling [4]. Most studies are in rats and mice; rodent models suggest effects on tendon, gut, muscle and nerve repair. The mechanism in humans is uncharacterized — only three small human pilot studies exist as of 2025, and none was a rigorous efficacy trial [2]. It does not act as a growth hormone.
Is BPC-157 a growth hormone?
No. BPC-157 is a gastric pentadecapeptide — it comes from a protein found in gastric juice. It does not directly release or mimic growth hormone. In cultured tendon cells it has been shown to increase growth-hormone-receptor signaling, which may contribute to the tendon-repair effects seen in animals [2], but that is a receptor-sensitization effect in a specific tissue type, not GH secretion. Ipamorelin, by contrast, is a genuine growth hormone secretagogue — it triggers GH release from the pituitary gland [11].
Does BPC-157 work immediately?
The published animal studies report effects over days to weeks rather than immediately. BPC-157 has a short elimination half-life (under 30 minutes in rats and dogs) [3], so each dose clears rapidly. The tissue-level changes in rodent models — angiogenesis, wound healing — are measured at intervals of days, not hours. Anecdotal reports from research-use communities often describe first noticeable effects within one to three weeks. No controlled human data characterize a timeline.
Does BPC-157 damage the liver?
There is no published evidence that BPC-157 damages the liver. The only human safety pilot — two adults given intravenous BPC-157 — found no change in hepatic biomarkers [1]. The rodent literature does not flag hepatotoxicity as a consistent finding. However, because the human evidence base is so small and BPC-157 is not an approved, regulated drug, its full safety profile in humans is genuinely unknown. Products from unregulated suppliers add an additional uncertainty about what is actually in any given sample [2].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a pulse of growth hormone release. It is described as 'the first selective growth hormone secretagogue' because, unlike earlier GHRPs, it does not meaningfully raise cortisol or prolactin even at doses far above its GH threshold [11]. It has never been approved as a drug anywhere, and its only Phase 2 trial missed its primary endpoint [8]. It is sold for laboratory research use only.
What does ipamorelin do for you?
In controlled research settings, ipamorelin's main documented effect is triggering a GH pulse from the pituitary gland — a single, discrete release peaking about 40 minutes after dosing in human volunteers [9]. In animal models, this GH-stimulating activity has been linked to dose-dependent increases in bone growth (in rats) [10] and to weight-loss protection in a ferret chemotherapy model [6]. In its one human efficacy RCT (postoperative bowel recovery), it did not statistically outperform placebo [8]. It is not approved for any human therapeutic use.
What is ipamorelin peptide?
Ipamorelin is a pentapeptide — a five-amino-acid chain — synthesized to mimic the GH-releasing action of the natural hormone ghrelin. Its chemical sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, where two of the five amino acids are D-form (mirror-image) versions that resist enzyme breakdown and improve stability. It belongs to the family of growth hormone secretagogues (GHS). It is also sometimes called NNC 26-0161 (its original Novo Nordisk research code). It is not the same as the combination 'CJC-1295/ipamorelin' blend — ipamorelin alone is a single, distinct peptide.
What are the risks of ipamorelin?
Known and theoretical cautions for ipamorelin include: (1) a class-level cardiovascular signal in rats from a related GHS-R1a agonist — dose-dependent myocardial changes after 28 days [7]; (2) GH-axis stimulation, which raises IGF-1 and theoretically concerns people with active or occult malignancies; (3) dual metabolic effects — both GH-mediated insulin resistance and a direct pancreatic islet effect — creating unpredictable glycemic impact in people with diabetes [7]; (4) the ghrelin-receptor mechanism is orexigenic (appetite-stimulating) and adipogenic in preclinical models; (5) no long-term human safety data exist. Its compounding-pharmacy pathway was curtailed in 2024 after the FDA reviewed the compound.
What is semaglutide?
Semaglutide is a 31-amino-acid acylated analogue of the natural incretin hormone GLP-1 (glucagon-like peptide-1). It is FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with obesity and established heart disease, and (since 2025) metabolic dysfunction-associated steatohepatitis. It shares about 94% sequence identity with native GLP-1 but is structurally modified to resist enzyme breakdown and bind albumin, giving it a half-life of about one week compared to GLP-1's two minutes — enabling once-weekly dosing [16][17].
What is semaglutide used for?
Approved indications (as of mid-2026): type 2 diabetes (glycemic control), chronic weight management in adults with obesity or overweight with at least one weight-related condition, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity/overweight but no diabetes [15], and metabolic dysfunction-associated steatohepatitis (MASH). The FLOW trial also showed 24% lower risk of major kidney-disease events in type 2 diabetes with chronic kidney disease [14]. The generic compound is the active molecule behind the approved subcutaneous and oral prescription products.
How does semaglutide work?
Semaglutide activates the GLP-1 receptor (GLP-1R), which is expressed in the pancreas (insulin secretion from beta cells, glucagon suppression from alpha cells), the brain (appetite reduction via hypothalamic and brainstem circuits), the gastrointestinal tract (delayed gastric emptying), and cardiovascular and renal tissues (pleiotropic protective effects). Its weight-lowering effect is primarily central: it activates anorexigenic neurons and inhibits orexigenic neurons in hypothalamic appetite circuits, reducing food intake and modifying food preferences — an effect that many patients describe as their 'food noise' going quiet [16][17].
How does semaglutide work for weight loss?
The weight-loss mechanism is primarily central nervous system signaling rather than a direct metabolic rate effect. Semaglutide crosses into the hypothalamus and brainstem where GLP-1 receptors modulate appetite: activating POMC/CART neurons (which signal fullness) and inhibiting NPY/AgRP neurons (which drive hunger). In the STEP 1 trial, this produced a mean −14.9% body-weight change at 68 weeks versus −2.4% for placebo in people with obesity [16]. Semaglutide also slows gastric emptying, which contributes to feeling full sooner. Weight regain after stopping semaglutide is substantial — the mechanism requires ongoing treatment.
What does a GHK-Cu peptide do?
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper complex) stimulates dermal fibroblasts to produce collagen, elastin, and glycosaminoglycans — the structural proteins and sugars that give skin its strength, elasticity, and hydration [21]. It also activates lysyl oxidase, which cross-links newly formed collagen fibers, and modulates matrix metalloproteinases (enzymes that break down old matrix). In gene-expression analysis it alters approximately 31.2% of human genes at a ≥50% change threshold, with broad up-regulation of wound-repair, antioxidant, and protein-quality-control pathways [19]. Most evidence is from in-vitro cell studies and small human topical trials.
What is GHK-Cu and how does it work?
GHK-Cu is a three-amino-acid peptide (Gly-His-Lys) bound to a copper(II) ion. It is found naturally in human plasma and declines with age (from ~200 ng/mL at age 20 to ~80 ng/mL at age 60) [21]. As a copper chaperone, it keeps copper in a stable, bioavailable form and delivers it to enzymes that need it — particularly lysyl oxidase for collagen cross-linking and superoxide dismutase for antioxidant defense. As a signaling molecule, it activates fibroblasts and keratinocytes at picomolar concentrations. The copper must be properly coordinated: free GHK without copper does not reproduce the key matrix-building effects.
Is GHK-Cu peptide really anti-aging?
It depends on how precisely you define 'anti-aging.' In small controlled human trials, topical GHK-Cu increases collagen production in 70% of treated subjects (versus 50% for vitamin C) [21] and a 6-month combination GHK-containing topical trial in 45 men with hair thinning increased hair count versus placebo [20]. Plasma GHK declines with age, which has prompted research into whether replenishing it topically or systemically could slow aging-related tissue changes — but the sweeping gene-level and 'reversal of aging' claims in marketing go well beyond what the controlled clinical evidence has established [18]. Honest answer: promising cell and small-trial data, not yet confirmed in large human trials.
What is the difference between GHK and GHK-Cu?
GHK is the free tripeptide: Glycine-Histidine-Lysine without any metal attached. GHK-Cu is GHK with a copper(II) ion coordinated through the histidine imidazole and the glycine-histidine amide nitrogen. The copper is not just along for the ride: most of the documented biological activities — including MMP-2 stimulation, lysyl oxidase activation, and antioxidant superoxide dismutase support — require the copper to be present and properly bound. Studies that use free GHK without copper may not reproduce findings from GHK-Cu studies, and the two are sometimes conflated in the literature. When you read a GHK-Cu study, check whether the copper-bound form was actually used [19].